Meeting
2021 ASCO Annual Meeting
The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Authors
Rachel Soyoun Kim
University of Toronto Division of Gynecologic Oncology, Princess Margaret Cancer Centre/University Health Network/Sinai Health Systems, Toronto, ON, Canada
Rachel Soyoun Kim , Janet Malcolmson , Xuan Li , Marcus Bernardini , Liat Frida Hogen , Taymaa May
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5543)
DOI
10.1200/JCO.2021.39.15_suppl.5543
Abstract #
5543
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
First Author: Gwenael Ferron
Poster
2023 ASCO Annual Meeting
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
First Author: Jason Silberman
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.
First Author: Roxane Mari
Poster
2018 ASCO Annual Meeting
Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).
First Author: Anna Fagotti